Effectiveness and safety of disitamab vedotin (RC48) in pretreated HER2-positive advanced breast cancer: A real-world experience in China.
Year: 2025
Type: article
Study design: Observational Study
Source: Journal of Clinical Oncology
Authors: Yiqun Li, Ying Wang, De Zeng, Yuan Wu, Xiwen Bi, Huafeng Kang, Feng Wang, Li Li, Yongmei Yin, Qiao Li, Xiaodong Gu, Huihui Li, Binghe Xu
Institutions: Chinese Academy of Medical Sciences & Peking Union Medical College, Sun Yat-sen Memorial Hospital, Cancer Hospital of Shantou University Medical College, Jiangsu Cancer Hospital, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Second Affiliated Hospital of Xi'an Jiaotong University, Zhengzhou University, First Affiliated Hospital of Zhengzhou University, Zhongnan Hospital of Wuhan University, Jiangsu Province Hospital, Shanxi Provincial Cancer Hospital, Shandong Tumor Hospital
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4410819724